Huhn Stephen L. has filed 4 insider transactions across 1 company since May 2024.
Most recent transaction: a grant/award of 110000 shares of Contineum Therapeutics, Inc. ($CTNM) on January 31, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 31, 2025 | Contineum Therapeutics, Inc. | $CTNM | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | A | Stock Option (right to buy) | 110000 | $0.00 | 110,000.0000 | 19,352,859 | 9999.99% | 0.57% |
| Aug. 13, 2024 | Contineum Therapeutics, Inc. | $CTNM | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | M | Class A Common Stock | 12800 | $1.01 | 12,800.0000 | 2,308,972 | 9999.99% | 0.55% |
| Aug. 13, 2024 | Contineum Therapeutics, Inc. | $CTNM | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | M | Stock Option (right to buy) | 12800 | $0.00 | 161,394.0000 | 2,308,972 | 7.35% | 0.55% |
| May 24, 2024 | Contineum Therapeutics, Inc. | $CTNM | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | A | Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 2,308,972 | 9999.99% | 4.33% |